查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413848

抗体治疗市场：按剂型、给药途径、来源、疾病领域和最终用户 - 2024-2030 年全球预测

Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗体治疗市场规模为2,487.9亿美元，2024年将达2,857.7亿美元，2030年将达6,575亿美元，复合年增长率为14.89%。

抗体治疗的全球市场

主要市场统计
基准年[2023] 2487.9亿美元
预测年份 [2024] 2857.7亿美元
预测年份 [2030] 6575亿美元
复合年增长率（%） 14.89%
抗体治疗药物市场-IMG1

抗体疗法是一类使用抗体来模拟或增强免疫系统对抗疾病的能力的医学治疗方法。抗体疗法的精确性使得客製化治疗能够提供比传统药物更高的特异性和更低的毒性，使其能够有效治疗多种疾病，包括癌症、自体免疫疾病和感染疾病。慢性病的增加和全球医疗成本的上升导致抗体疗法的采用增加。然而，高昂的开发成本以及漫长而复杂的监管核准限制了抗体疗法的普及。然而，医疗技术的进步提高了抗体的生产效率。此外，新一代抗体的出现以及政府对癌症治疗和护理的支持措施预计将为抗体治疗市场带来潜在商机。

区域洞察

在美洲，抗体治疗市场在完善的研发生态系统、广泛的专利组合和高昂的医疗成本的支持下呈现强劲成长。此外，美洲是许多大型生物製药公司的所在地，这些公司正在投入大量资源来开发单株抗体和新药。在亚太地区，由于医疗基础设施的改善和慢性病的增加，对抗体治疗的需求正在迅速增加。此外，由于强大的研究机构和政府支持政策的支持，个人化医疗和抗体开发取得了进步，亚太地区的抗体治疗市场正在成长。欧盟（EU）国家凭藉其强大的製药工业、广泛的研究措施和全面的智慧财产权框架，在抗体治疗市场中占据着举足轻重的地位。此外，中东和非洲国家正在投资最先进的医疗设施和医疗创新。

FPNV定位矩阵

FPNV 定位矩阵对于评估抗体治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗体治疗市场供应商的现状进行深入而深入的研究。透过仔细比较和分析供应商在整体收入、客户群和其他关键指标方面的贡献，让企业更深入地了解供应商收益以及他们在争夺市场占有率时面临的挑战。此外，该分析也为该产业的竞争特征提供了宝贵的见解，包括在研究基准年观察到的累积、分散优势和合併特征等因素。这种扩展的详细程度使供应商能够做出更明智的决策并制定有效的策略来参与市场竞争。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2- 市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管核准、专利状况和製造能力进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-抗体治疗市场的市场规模和预测是多少？

2-抗体治疗市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-抗体治疗市场的技术趋势和法律规范是什么？

4-抗体治疗市场主要供应商的市场占有率是多少？

5-进入抗体治疗市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 各种癌症和感染疾病的发生率增加
      • 世界各地的药物研发活动不断增加
      • 政府促进获得抗体治疗和疗法的倡议
    • 抑制因素
      • 抗体治疗产品回想的发生率与严格的核准指引有关
    • 机会
      • 抗体疗法的临床开发进展
      • 新抗体疗法和治疗方法的核准仍在继续
    • 任务
      • 各种治疗方法效果不足及副作用
  • 市场区隔分析
    • 剂型：单株抗体的大量使用，并获得众多监管机构核准用于临床
    • 给药途径：增加静脉注射抗体治疗的使用
    • 来源：由于生物相容性，人类抗体的使用增加
    • 疾病领域：感染疾病抗体疗法的使用迅速增加
    • 最终用户：医院使用抗体疗法的方式正在不断发展
  • 市场趋势分析
    • 抗体疗法的先进研究和开发活动得到了政府资助和美洲全球知名製药公司的合作努力的支持。
    • 慢性病和感染疾病负担日益增加，亚太地区对抗体治疗的需求不断增加
    • 生技公司在欧洲、中东和非洲扩张，临床试验进展
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章 抗体治疗药物市场：按剂型

  • 介绍
  • 抗体片段
  • 双特异性抗体
  • 单株抗体
  • 多克隆抗体

第七章 抗体治疗药物市场：依给药途径分类

  • 介绍
  • 静脉
  • 皮下的

第八章抗体治疗市场：依来源分类

  • 介绍
  • 嵌合体
  • 人类
  • 人性化

第九章抗体治疗药物市场：依疾病领域

  • 介绍
  • 自体免疫疾病与发炎疾病
  • 血液学
  • 免疫学
  • 神经病学
  • 肿瘤学
  • 骨学

第10章抗体治疗市场：依最终用户分类

  • 介绍
  • 医院
  • 疗养院

第十一章美洲抗体治疗药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太抗体治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲抗体治疗药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析
    • 併购
    • 合约、合作和伙伴关係
    • 新产品发布和功能增强
    • 投资、资金筹措
    • 奖项/奖励/扩展

第15章竞争组合

  • 主要公司简介
    • AbbVie Inc.
    • AbCellera Biologics Inc.
    • Adaptimmune Therapeutics PLC
    • ADC Therapeutics SA
    • Aenova Holding GmbH
    • Almac Group Limited
    • Amgen Inc.
    • Antikor Biopharma
    • Argenx SE
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Biogen Inc.
    • BioNTech SE
    • Bristol-Myers Squibb Company
    • Confo Therapeutics
    • DH Life Sciences, LLC
    • DotBio Pte. Ltd.
    • Eli Lilly and Company
    • Emergent BioSolutions Inc.
    • Evonik Industries AG
    • F. Hoffmann-La Roche Ltd.
    • GE HealthCare Technologies, Inc.,
    • Genmab A/S
    • GlaxoSmithKline PLC
    • Grifols, SA
    • Incyte Corporation
    • iTeos Therapeutics, Inc.
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • Merus NV
    • MoonLake Immunotherapeutics AG
    • MorphoSys AG
    • Novartis AG
    • Novo Nordisk A/S
    • Numab Therapeutics AG
    • Pfizer Inc.
    • PharmAbcine Inc.
    • Pyxis Oncology, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • SAB Biotherapeutics, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.
    • TRIO Pharmaceuticals Inc.
    • UCB SA
    • Xencor, Inc.
  • 主要产品系列

第十六章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-A42893A596EA

[188 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.

Global Antibody Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 248.79 billion
Estimated Year [2024] USD 285.77 billion
Forecast Year [2030] USD 657.50 billion
CAGR (%) 14.89%
Antibody Therapeutics Market - IMG1

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Format
    • Antibody Fragment
    • Bispecific Antibody
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Route of Administration
    • Intravenous
    • Subcutaneous
  • Source
    • Chimeric
    • Human
    • Humanized
  • Disease Areas
    • Autoimmune & Inflammatory Diseases
    • Hematology
    • Immunology
    • Neurology
    • Oncology
    • Osteology
  • End User
    • Hospitals
    • Long-term Care Facilities
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antibody Therapeutics Market?

4. What is the market share of the leading vendors in the Antibody Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antibody Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of various cancers and infectious diseases
      • 5.1.1.2. Increasing number of drug discovery activities worldwide
      • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
      • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
    • 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
    • 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
    • 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
    • 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
  • 5.3. Market Trend Analysis
    • 5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
    • 5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
    • 5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibody Therapeutics Market, by Format

  • 6.1. Introduction
  • 6.2. Antibody Fragment
  • 6.3. Bispecific Antibody
  • 6.4. Monoclonal Antibody
  • 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

  • 8.1. Introduction
  • 8.2. Chimeric
  • 8.3. Human
  • 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

  • 9.1. Introduction
  • 9.2. Autoimmune & Inflammatory Diseases
  • 9.3. Hematology
  • 9.4. Immunology
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Osteology

10. Antibody Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player
    • 14.3.1. Merger & Acquisition
      • 14.3.1.1. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
      • 14.3.1.2. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
      • 14.3.1.3. Merck to Develop mAb Through USD 10.8 Billion Acquisition
    • 14.3.2. Agreement, Collaboration, & Partnership
      • 14.3.2.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
      • 14.3.2.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
      • 14.3.2.3. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
      • 14.3.2.4. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
      • 14.3.2.5. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
    • 14.3.3. New Product Launch & Enhancement
      • 14.3.3.1. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 14.3.4. Investment & Funding
      • 14.3.4.1. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
      • 14.3.4.2. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
      • 14.3.4.3. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 14.3.5. Award, Recognition, & Expansion
      • 14.3.5.1. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AbbVie Inc.
    • 15.1.2. AbCellera Biologics Inc.
    • 15.1.3. Adaptimmune Therapeutics PLC
    • 15.1.4. ADC Therapeutics SA
    • 15.1.5. Aenova Holding GmbH
    • 15.1.6. Almac Group Limited
    • 15.1.7. Amgen Inc.
    • 15.1.8. Antikor Biopharma
    • 15.1.9. Argenx SE
    • 15.1.10. Astellas Pharma Inc.
    • 15.1.11. AstraZeneca PLC
    • 15.1.12. Baxter International Inc.
    • 15.1.13. Bayer AG
    • 15.1.14. Becton, Dickinson and Company
    • 15.1.15. Bio-Rad Laboratories, Inc.
    • 15.1.16. Biogen Inc.
    • 15.1.17. BioNTech SE
    • 15.1.18. Bristol-Myers Squibb Company
    • 15.1.19. Confo Therapeutics
    • 15.1.20. DH Life Sciences, LLC
    • 15.1.21. DotBio Pte. Ltd.
    • 15.1.22. Eli Lilly and Company
    • 15.1.23. Emergent BioSolutions Inc.
    • 15.1.24. Evonik Industries AG
    • 15.1.25. F. Hoffmann-La Roche Ltd.
    • 15.1.26. GE HealthCare Technologies, Inc.,
    • 15.1.27. Genmab A/S
    • 15.1.28. GlaxoSmithKline PLC
    • 15.1.29. Grifols, S.A.
    • 15.1.30. Incyte Corporation
    • 15.1.31. iTeos Therapeutics, Inc.
    • 15.1.32. Johnson & Johnson Services, Inc.
    • 15.1.33. Merck KGaA
    • 15.1.34. Merus N.V.
    • 15.1.35. MoonLake Immunotherapeutics AG
    • 15.1.36. MorphoSys AG
    • 15.1.37. Novartis AG
    • 15.1.38. Novo Nordisk A/S
    • 15.1.39. Numab Therapeutics AG
    • 15.1.40. Pfizer Inc.
    • 15.1.41. PharmAbcine Inc.
    • 15.1.42. Pyxis Oncology, Inc.
    • 15.1.43. Regeneron Pharmaceuticals, Inc.
    • 15.1.44. SAB Biotherapeutics, Inc.
    • 15.1.45. Sanofi S.A.
    • 15.1.46. Takeda Pharmaceutical Company Limited
    • 15.1.47. Thermo Fisher Scientific Inc.
    • 15.1.48. TRIO Pharmaceuticals Inc.
    • 15.1.49. UCB S.A.
    • 15.1.50. Xencor, Inc.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
  • FIGURE 14. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 237. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. ANTIBODY THERAPEUTICS MARKET LICENSE & PRICING